These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 20381846

  • 1. Cost comparison between watchful waiting with active surveillance and active treatment of clinically localized prostate cancer.
    Corcoran AT, Peele PB, Benoit RM.
    Urology; 2010 Sep; 76(3):703-7. PubMed ID: 20381846
    [Abstract] [Full Text] [Related]

  • 2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
    Wilt TJ, Brawer MK, Barry MJ, Jones KM, Kwon Y, Gingrich JR, Aronson WJ, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Fox S.
    Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
    [Abstract] [Full Text] [Related]

  • 3. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).
    Andersson SO, Andrén O, Lyth J, Stark JR, Henriksson M, Adami HO, Carlsson P, Johansson JE.
    Scand J Urol Nephrol; 2011 Apr; 45(3):177-83. PubMed ID: 21265595
    [Abstract] [Full Text] [Related]

  • 4. Use of additional treatment for prostate cancer after radical prostatectomy, radiation therapy, androgen deprivation, or watchful waiting.
    Berge V, Thompson T, Blackman D.
    Scand J Urol Nephrol; 2007 Apr; 41(3):198-203. PubMed ID: 17469027
    [Abstract] [Full Text] [Related]

  • 5. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R, Klein E.
    Cancer J Sci Am; 1997 Apr; 3(2):78-87. PubMed ID: 9099457
    [Abstract] [Full Text] [Related]

  • 6. Economic analysis of active surveillance for localized prostate cancer.
    Kim S, Dall'Era MA, Evans CP.
    Curr Opin Urol; 2012 May; 22(3):247-53. PubMed ID: 22388666
    [Abstract] [Full Text] [Related]

  • 7. Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy.
    Kulkarni GS, Lockwood G, Evans A, Toi A, Trachtenberg J, Jewett MA, Finelli A, Fleshner NE.
    Cancer; 2007 Jun 15; 109(12):2432-8. PubMed ID: 17497649
    [Abstract] [Full Text] [Related]

  • 8. Active surveillance vs. treatment for low-risk prostate cancer: a cost comparison.
    Eldefrawy A, Katkoori D, Abramowitz M, Soloway MS, Manoharan M.
    Urol Oncol; 2013 Jul 15; 31(5):576-80. PubMed ID: 21616691
    [Abstract] [Full Text] [Related]

  • 9. Management and survival of screen-detected prostate cancer patients who might have been suitable for active surveillance.
    Roemeling S, Roobol MJ, Postma R, Gosselaar C, van der Kwast TH, Bangma CH, Schröder FH.
    Eur Urol; 2006 Sep 15; 50(3):475-82. PubMed ID: 16713065
    [Abstract] [Full Text] [Related]

  • 10. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
    Ward JF, Slezak JM, Blute ML, Bergstralh EJ, Zincke H.
    BJU Int; 2005 Apr 15; 95(6):751-6. PubMed ID: 15794776
    [Abstract] [Full Text] [Related]

  • 11. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
    Johansson E, Bill-Axelson A, Holmberg L, Onelöv E, Johansson JE, Steineck G, Scandinavian Prostate Cancer Group Study No 4.
    Eur Urol; 2009 Feb 15; 55(2):422-30. PubMed ID: 18783877
    [Abstract] [Full Text] [Related]

  • 12. Active surveillance with selective delayed intervention for favorable risk prostate cancer: clinical experience and a 'number needed to treat' analysis.
    Klotz LH, Nam RK.
    Can J Urol; 2006 Feb 15; 13 Suppl 1():48-55. PubMed ID: 16526983
    [Abstract] [Full Text] [Related]

  • 13. Cumulative cost pattern comparison of prostate cancer treatments.
    Wilson LS, Tesoro R, Elkin EP, Sadetsky N, Broering JM, Latini DM, DuChane J, Mody RR, Carroll PR.
    Cancer; 2007 Feb 01; 109(3):518-27. PubMed ID: 17186528
    [Abstract] [Full Text] [Related]

  • 14. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes?
    van den Bergh RC, Steyerberg EW, Khatami A, Aus G, Pihl CG, Wolters T, van Leeuwen PJ, Roobol MJ, Schröder FH, Hugosson J, Swedish and Dutch sections of the European Randomized Study of Screening for Prostate Cancer.
    Cancer; 2010 Mar 01; 116(5):1281-90. PubMed ID: 20066716
    [Abstract] [Full Text] [Related]

  • 15. Conventional treatments of localized prostate cancer.
    Zerbib M, Zelefsky MJ, Higano CS, Carroll PR.
    Urology; 2008 Dec 01; 72(6 Suppl):S25-35. PubMed ID: 19095125
    [Abstract] [Full Text] [Related]

  • 16. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics.
    Krakowsky Y, Loblaw A, Klotz L.
    J Urol; 2010 Jul 01; 184(1):131-5. PubMed ID: 20478589
    [Abstract] [Full Text] [Related]

  • 17. [Management of prostate cancer with indolent biological potential: from watchful waiting to active surveillance].
    Leibovici D, Lindner A, Stay K, Zisman A.
    Harefuah; 2006 Oct 01; 145(10):763-7, 781, 780. PubMed ID: 17111715
    [Abstract] [Full Text] [Related]

  • 18. Short-term outcomes of the prospective multicentre 'Prostate Cancer Research International: Active Surveillance' study.
    van den Bergh RC, Vasarainen H, van der Poel HG, Vis-Maters JJ, Rietbergen JB, Pickles T, Cornel EB, Valdagni R, Jaspars JJ, van der Hoeven J, Staerman F, Oomens EH, Rannikko A, Roemeling S, Steyerberg EW, Roobol MJ, Schröder FH, Bangma CH.
    BJU Int; 2010 Apr 01; 105(7):956-62. PubMed ID: 19817747
    [Abstract] [Full Text] [Related]

  • 19. Time trends and characteristics of men choosing watchful waiting for initial treatment of localized prostate cancer: results from CaPSURE.
    Harlan SR, Cooperberg MR, Elkin E, Lubeck DP, Meng M, Mehta SS, Carroll PR.
    J Urol; 2003 Nov 01; 170(5):1804-7. PubMed ID: 14532780
    [Abstract] [Full Text] [Related]

  • 20. The watchful waiting management option for older men with prostate cancer: state of the science.
    Wallace M, Bailey D, O'Rourke M, Galbraith M.
    Oncol Nurs Forum; 2004 Nov 16; 31(6):1057-66. PubMed ID: 15547629
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.